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SecretoglobinHigh-throughput sequencing of RNA (RNA-Seq) was developed primarily to analyze global gene expression in
different tissues. It is also an efﬁcient way to discover coding SNPs and when multiple individuals with different
genetic backgrounds were used, RNA-Seq is very effective for the identiﬁcation of SNPs. The objective of this
study was to perform SNP and INDEL discoveries in human airway transcriptome of healthy never smokers,
healthy current smokers, smokers without lung cancer and smokers with lung cancer. By preliminary compara-
tive analysis of these four data sets, it is expected to get SNP and INDEL patterns responsible for lung cancer. A
total of 85,028 SNPs and 5738 INDELs in healthy never smokers, 32,671 SNPs and 1561 INDELs in healthy current
smokers, 50,205 SNPs and 3008 INDELs in smokers without lung cancer and 51,299 SNPs and 3138 INDELs in
smokers with lung cancer were identiﬁed. The analysis of the SNPs and INDELs in genes that were reported
earlier as differentially expressed was also performed. It has been found that a smoking person has SNPs at posi-
tion 62,186,542 and 62,190,293 in SCGB1A1 gene and 180,017,251, 180,017,252, and 180,017,597 in SCGB3A1
gene and INDELs at position 35,871,168 in NFKBIA gene and 180,017,797 in SCGB3A1 gene. The SNPs identiﬁed
in this study provides a resource for genetic studies in smokers and shall contribute to the development of a per-
sonalizedmedicine. This study is only a preliminary kind andmore vigorous data analysis and wet lab validation
are required.
© 2014 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Next-generation sequencing (NGS) technology has produced
immense biological data and has shed light on the path towards person-
alized medicine (Liu et al., 2013). NGS technology is used extensively
for various applications such as: de novo sequencing, disease mapping,
and quantifying expression levels through RNA sequencing etc.
(Nielsen et al., 2011). The general application of NGS is: SNP and other
variations discoveries, whose downstream usefulness is linkage map
construction, genetic diversity analyses, association mapping and
marker assisted selection. They make up over 90% of all human genetic
variations, implicated in phenotype differences, risk to certain diseases
and response to drugs. They also serve as popular biomarkers in
pharmacogenomic studies to understand inter-individual differences
in response to various treatments. Even synonymous SNPs also inﬂu-
ence mRNA stability, protein conformation and protein regulation
(Sauna and Kimchi-Sarfaty, 2011). Therefore, it is essential to obtain
accurate SNP and INDEL proﬁle information through advancedmethods-KBC Research Centre, Anna
a. Tel./fax: +91 44 22232711.
pen access article under the CC BY-Nsuch as next-generation sequencing technologies (Yu and Sun, 2013).
(See Fig. 1.)
The airway epithelium constitutes an essential tissue barrier
protecting the lung from inhaled environmental challenges. Tobacco
smoking is the dominant causative for lung/pulmonary cancer and
because of this, the epithelial cells of the respiratory tractwere impaired
in lung cancer patients (Beane et al., 2011a; Shields, 1999; Spira et al.,
2004; Miyazu et al., 2005). It creates a ﬁeld of injury in epithelial cells
that line the respiratory tract and is a causative factor for chronic
obstructive pulmonary disease and lung cancer, with 10% to 20% of
smokers developing these diseases. A smoking-related gene and
miRNA expression alteration in the cytologically normal large and
small airway epithelium has been proved by usingmicroarray exper-
iments. These expression alterations have been categorized by their
degree of reversibility upon smoking cessation, providing insights
into genomic changes that may account for persistent lung cancer
risk. Similar gene expression alterations have been found in the epithe-
lia of the nose and mouth of smokers (Guo et al., 2004). The serious
challenge in lung cancer is that the early detection and anomalous
changes in the immune system, persistent inﬂammation, alteration in
chemokine receptor signaling and cytokine trafﬁcking are the most
essential features in disease pathogenesis (Beane et al., 2011b; KunkelC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Schematic representation of workﬂow of this current study.
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et al., 2010; Beane et al., 2007; Zhang et al., 2010; Harvey et al., 2007).
Genes S100A8 and S100A9, which are known to be involved in the
inﬂammatory response in the lung, and CYP4F2, a member of the
cytochrome P450 family of enzymes that play a role in xenobiotic path-
ways, were found to be upregulated in smokers by both RNA-Seq and
qRT-PCR. Similarly, the expression of the CCL20, IL8, NFKB1A, and
SCGB3A1 immunomodulatory genes were found to be upregulated in
the normal airway of patients with lung cancer (Beane et al., 2011b).
Genes involved in lung cancer from literature studies were collected
and themost relevant genes in lung cancer include the following: EGFR,
KRAS, MET, LKB1, BRAF, PIK3CA, ALK, RET, and ROS1. Other frequently
mutated genes include tyrosine kinases such as EGFR homolog ERBB4
and multiple ephrin receptor genes such as EPHA3, VEGFR2 (KDR),
and NTKR. Recent advances in the ﬁelds of mutational analysis and
molecularly targeted therapy made it possible to develop new receptor
kinase inhibitors such as erlotinib and geﬁtinib (against EGFR) andmost
recently crizotinib (against ALK) and antibodies such as ascetuximab
(against EGFR) and bevacizumab (against VEGF).
In the current study, SNPs and INDELs were analyzed in four differ-
ent categories of samples (healthy never smokers, current smokers,
smokers with lung cancer and smoking without lung cancer) processed
by RNA Seq technology, these following data procured from Frank
Schembri et al., 2011 (Beane et al., 2011a). Reads were pre-processed
by quality checking and ﬁltering of low quality reads. The processed
paired-end reads were mapped to reference genome hg19. Reads that
mapped to referencewere detached and the replica readswere removed
to knock out the false SNPs and INDELs. SNP calling was implementedwith default parameters and it was annotated to predict the functional
impact of variants. Genes that showed distinctive expression by differ-
ential expression, gene analysis and substantiated through microarray
were reported earlier in these samples (Beane et al., 2011a). The vari-
ants existing in the samples and SNPs/INDELs which are expedient to
cause lung cancer in smoking person were identiﬁed. This is only a pre-
liminary analysis and further in depth data analysis and wet lab exper-
iments would help for further validation.
2. Materials and methods
2.1. Source of NGS data
ThemRNA/transcriptome sequence of human airway epithelial cells
was attained in the interim of bronchoscopy undergoing lung nodule
resection surgery. These data were retrieved from prior study tabu-
lated in Table 1 (Beane et al., 2011a). The reads were paired-end
and sequenced through pooled sequence approach using Illumina
technology.
The differential expression analysis was performed in these samples.
The genes that are differently expressed by RNA differential expression
analysis and microarray analysis between these samples are tabulated
in Table 2. Pathways and molecular functions such as oxidoreductase
activity, metabolism of xenobiotics by cytochrome P450 and retinolme-
tabolism were enriched among genes differentially expressed between
current and never smokers. Cytokine–cytokine receptor interaction,
chemokine signaling pathway, and cell adhesion molecules were
enriched among genes differentially expressed between smokers with
Table 1
Details of samples used for NGS data analysis.
Data accession Category Details Age Status
SRR192333 Healthy never smokers 3 female ~29 Healthy normal
SRR192334 Current smokers 1 male 2 female ~41.7 Smokers
SRR192335 Smokers without lung cancer 1 male 2 female ~49 2 former and 1 current smokers
SRR192336 Smokers with lung cancer 2 male 1 female ~64.7 2 former and 1 current smokers with cancer
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other alternations such as fusion genes, copy number variations and
methylation.
2.2. Data retrieval
The next generation paired-end sequencing data were procured
from the DDBJ DRA database. The data are freely accessible with the
successive accession numbers SRR192333, SRR192334, SRR192335,
SRR192336 for four different categories of samples such as healthy
never smokers, healthy current smokers, smokers without lung cancer
and smokers with lung cancer which have been analyzed in this
investigation.
2.3. Pre-processing
Next generation sequencing approach generates plenty of sequence
data in a single experimental run. Hence the data encompasses sequence
artifacts that include read errors, poor quality reads and primer/adaptor
contamination which have an impact on downstream investigation.
Henceforth the quality of data is very decisive otherwise they may lead
to spurious conclusions. The initial step after accomplishing the sequenc-
ing run is to assess the base quality and to trim or correct bases that do
not reconcile the delineated from required speciﬁcation. Pre-processing
was executed using NGSQC toolkit to assess the quality of the data,
examine the distribution of nucleotide, and percolate the low quality
reads based on sequence constitution (Patel and Jain, 2012).
2.4. Alignment/mapping
Various groups effectively developed algorithms and software kit
to execute alignment and mapping. In this work, we used Burrows–
Wheeler Aligner to efﬁciently align short sequencing reads versus
human reference genome hg19 (Pabinger et al., 2013; Li and Durbin,
2009). The accurately mapped reads were detached using the Filter
SAM program in SAMtools and the duplicates were discarded using
Mark duplicates in Picard tool (Li et al., 2009).
2.5. Variant calling
SNP, INDEL and structural divergent regions were precisely pin-
pointed using a variant calling process between four different categories
of samples and the reference genome. In this study, we implementedTable 2
List of differentially expressed genes in diverse sample.
gene symbol Gene name Location
S100A8 Calgranulin A Chr1: 153,362,50–153,363,664
S100A9 Calgranulin B Chr1: 153,330,330–153,333,503
CYP4F2 Cytochrome p450 Chr19: 15,988,834–6,008,885
NFKB1A1 NFKB inhibitor Chr14: 35,870,717–35,873,952
SCGB1A1 Secretoglobin Chr11: 62,172,575–62,190,667
SCGB3A1 Secretoglobin Chr5: 180,017,103–180,018,540
CCL20 Chemokine Chr2: 228,678,558–228,682,272
IL8 Interleukin 8 Chr4: 74,606,223–74,609,433
RP11-295J3.2 ncRNA Chr10: 127,660,757–27,661,695
CTD-2325P2.2 Pseudogene Chr14: 69,159,807–69,160,300variant calling using Genome Analysis Toolkit Uniﬁed Genotypic caller
(GATK-UGT) (DePristo et al., 2011) and alignments were recalibrated
around insertion/deletion region according to Freud-scaled quality
scores. GATK-UGT generates output in VCF format. Along with the SNP
and its position, it also reports additional information about the called
SNPs, such as quality by depth (coverage), mapping quality, read depth,
and genotype quality that represent the quality of the called SNPs
(Ruffalo et al., 2011; Yu and Sun, 2013).
2.6. Variant annotation
It is essential to envision that the possibility of the functional impact
of variants in an automated fashion is becoming progressively critical.
The tools used for annotation are as follows: ANNOVAR is an efﬁcient
tool to elucidate functional residual of genetic variation and illustrated
based on gene and its location and type of variation (Wang et al.,
2010). SIFT was used to predict the effect of amino acid substitutions
on the protein function (Ng and Henikoff, 2001). PolyPhen-2 detects
the impact of structural changes intern how it is affecting the protein
function by divergent sequence and homology based phylogenetic
methods (Adzhubei et al., 2011).
3. Results and discussion
A simple pipeline to perceive SNPs and INDELs includes, pre-
processing the sequence data and ﬁltering low quality bases, mapping
reads to the human reference genome, and post-processing of the align-
ment results in order to ﬁnd the effect of variation.
3.1. Pre-processing
Initially the sequencing quality was scrutinized using FastQC tool.
NGSQC toolkit was used to ﬁlter the low quality reads and discard the
primer/adapter contaminated reads with default parameters. After ﬁl-
tering based on the quality score, 20.2 million reads in healthy never
smokers, 10.3 million reads in healthy current smokers, 10.8 million
reads in smokers without lung cancer and 10.7million reads in smokers
with lung cancer were retained and used for further analysis.
3.2. Alignment
Short sequencing readsweremapped to the annotated human refer-




Upregulation in smokers with lung cancer
Differentially expressed smokers with lung cancer
Upregulation in smokers with lung cancer
Upregulation in smokers with lung cancer
Upregulation in smokers with lung cancer
Down regulation in smokers with lung cancer and smokers
Upregulation in smokers with lung cancer, Down regulation in smokers
Table 3
Number of SNPs present in four categories.
Category SNP Transition Transversion Ti/Tv ratio
Healthy never smokers 85,028 55,314 29,714 1.86
Healthy current smokers 32,671 21,185 11,486 1.84
Smokers without lung cancer 50,205 32,820 17,385 1.88
Smokers with lung cancer 51,299 33,063 18,236 1.81
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SAM by setting the ﬂag values in SAMtool. The main rationales for
these unmapped reads are sequencingﬂaws, uneven quality of the sam-
ple preparations, physical gap of the reference and the deﬁnedmapping
criteria. SAMtools ﬂagstat was used to implement elementary statistics
on aligning binary alignment (BAM) ﬁles. Among 44,503,612 reads,
about 89.36% were aligned against hg19 and the properly mapped
reads were 72.95% in healthy never smokers. Among 27,548,608 reads
about 87.74% were aligned and properly mapped reads were 71.48% in
healthy current smokers. Among 37,108,950 reads about 90.72% were
aligned and properly mapped reads were 77.13% in smokers without
lung cancer. Among 35,174,558 reads about 90.92% were aligned and
properly mapped reads were 77% in smokers with lung cancer. After
performing alignment, SAMtools was used to remove duplicate reads
(Li et al., 2009).
Short-read alignment tools often misalign reads around INDELs,
which in many cases results in mismatches. Local realignment around
INDELs revamps the accuracy of INDEL calling. Local realignment, elim-
inates millions of mostly false positive variants while preserving nearly
all truly variable sites. To attain perfect call set possible realignment and
recalibration were done using INDEL REALIGNER and TABLE RECALI-
BRATION tools incorporated within GATK. The recalibrated alignment
ﬁles were then used for SNP disclosure.3.3. Variant calling
3.3.1. SNP/INDEL calling and annotation
The variant discovery software suite developed by the 1000Genomes
Project, the Genome Analysis Tool Kit Uniﬁed genotype caller (GATK-
UGT) was used to identify SNPs and INDEL. GATK shows a relatively
higher positive calling rate and sensitivity when compared to the others,
and tends to callmore SNPs and lower the false detection. The number of
SNPs identiﬁed using GATK-UGT is tabulated in Table 3.
It was proclaimed that Ti/Tv ratio for a random variation resulting
from systematic errors in the sequencing technology, alignment artifacts
and data processing failures should be close to 0.5 (Ni et al., 2012; Ding
et al., 2010). In the current study, transition to transversion ratio ranges
from 1.81 to 1.88 that signiﬁes that SNPs were likely resulting from trueTable 4
Number of Known and Novel SNPs/INDEL present in all the four categories.
Category Total SNPs Known SNPs No
Healthy never smokers 85,028 37,635 47
Healthy current smokers 32,671 14,396 18
Smokers without lung cancer 50,205 21,914 28
Smokers with lung cancer 51,299 21,451 29
Table 5
SNPs/INDEL present in exonic/functional region.
Category Synonymous-SNP Non-synonymous-SNP Frameshift d
Healthy never smokers 3116 3234 71
Healthy current smokers 1419 1429 23
Smokers without lung cancer 1830 2061 46
Smokers with lung cancer 1902 2058 48nucleotide polymorphism. SNPwas sorted based on functional classes as
missense, nonsense and silentmutations. Missensemutationwas higher
than silent andnon-sensemutations. The number ofmissensemutations
in healthy never smokers was 8571, healthy current smokers was 3005,
smokers without lung cancer was 3725 and smokers with lung cancer
was 3930. Further analysis with this missense mutation can identify
mutated genes culpable for disease. Using ANNOVAR, annotation was
performed against dbSNP to identify the known SNPs. SNPs which
were not found in dbSNP are considered to be novel. The number of
known and novel SNPs/INDELwas tabulated in Table 4. INDELwas called
using GATK tool with the default parameters. All the QUAL scores were
found to be greater than 30 and read depth approximately ranges from
20–250 which was ordinarily used as principle for calling variants in
GATK. The number of insertions was found to be double than deletions
in all samples. INDEL annotation was performed using an ANNOVAR
tool to discover the known and novel INDELs and is tabulated in Table 4.
The annotation was performed based on genomic location and the
SNPs and INDELSwere distributed in exonic, intronic, intergenic, down-
stream, upstream, UTR3, UTR5, and splicing region. SNPs/INDELs found
in the exonic region are of most inﬂuential, variation in the coding
region leads to protein non-functional and it is tabulated in Table 5.
INDELs found in exonic region were classiﬁed into groups as frameshift
deletion and insertion, non-frameshift deletion and insertion and are
tabulated in Table 5. The frameshift mutation results in abnormal pro-
tein products and changes the function and its regulation.3.3.2. Analysis of differentially expressed genes
SNPs and INDELswere found in the following genes such as S100A8,
S100A9, IL8, NFKB1A, SCGB1A1 and SCGB3A1. CYP4F2, CCL20, RP11-
295J3.2, and CTD-2325P2.2 genes do not have any SNPs and INDELs.
S100A8 and S100A9 genes are calcium and zinc binding proteins,
which play a prominent role in regulation of inﬂammatory response
as well as in cancer development and differential expression of these
genes is associated with the disease cystic ﬁbrosis (Ni et al., 2012; Ding
et al., 2010; Ding and Kaminsky, 2003; Lim et al., 2009; Hsu et al., 2009;
Henke et al., 2006). IL8 plays an essential role in pathogenesis of bronchi-
olitis, a common respiratory tract disease. NFKB1A is involved in inﬂam-
matory response and cancer. SCGB1A1 is a member of secretoglobin
family and defects in this gene are associated with susceptibility to asth-
ma, lung disease, respiratory failure etc. (Sjodin et al., 2003). SCGB3A1 is
involved in regulation of cell proliferation and includes cytokine activity.
The number of SNPs and INDELs foundwithin these differential expressed
genes is tabulated in Table 6.
S100A8, S100A9, IL8, NFKB1A and SCGB3A1 geneswere upregulated
in the disease pathogenesis. Based on the category of sample the com-
mon variation which is present in smokers with lung cancer, smokers
without lung cancer and current smokers was tabulated in Table. 7.vel SNPs Total INDELs Known INDELs Novel INDELs
,393 5738 2305 3433
,275 1561 654 910
,291 3008 1300 1708
,848 3138 1363 1775






Number of SNPs and INDELs present in differentially expressed genes.
Category SNPs INDELs
Healthy never smokers 39 14
Healthy current smokers 29 3
Smokers without lung cancer 27 7
Smokers with lung cancer 43 10
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following changes detected in regulatory region that may affect the
regulation of the gene.
When evaluating the changes between smokers with lung cancer
and without lung cancer, we detect some discrepancy in the IL8 regula-
tory region. By comparing the entire sample, some of the variations are
present only in smokers with lung cancer.
The effect of non-synonymous aberrations can be anticipated using
SIFT and PolyPhen-2. SIFT predicts the potential impact of amino
acid substitution on protein function based on sequence homology.
PolyPhen-2 also detects the effect of non-synonymous variation
based on homologous sequence and structure based prediction.
SNP present in this position 180,017,251, amino acid changes alanine
to serine predicted to be deleterious based on Polyphen-2 prediction.
Frameshift insertion in the position 180,017,797 envisioned to be
damaging the protein function. The above SNPs were not reported
in catalogue of somatic mutation in cancer (COSMIC) database
(Forbes et al., 2011).
4. Conclusion
Transcriptome analysis using next generation sequencing is the
most competent and cost effective for identiﬁcation of SNPs and INDELs.
In the current study, ourmain focus was to analyze the variants existing
in the genes which were disclosed earlier as differentially expressed.
We found 5 SNPs and 2 INDELs in SCGB1A1, SCGB3A1 and NFKB1A
genes which were present only in smokers with lung cancer. Hence a
smoking person having this set of SNPs and INDELs is a preliminary
signature for the disease pathogenesis. Understanding an individual's
genetic makeup is believed to be the key role in personalized medicine
to maximize drug efﬁcacy and minimize adverse side effects. In the
future, an individual's genome will be sequenced to predict the future
health of the individual and to develop personalizedmedical treatments
that are tailored to work with the genetic variation that is detected
(Mullaney et al., 2010). Extending this study to a large group of popula-
tion will be useful for developing personalized medicine. In the future,
we are planning to study the stability of wild and mutant protein forTable 7
SNPs and INDELs present in different categories.
Chr Position dbSNP Ref/Alt Categ
1 153,333,376 Novel A/C CS +
4 74,606,669 rs2227307 T/G CS +
1 153,362,719 Novel T/TC CS +
4 74,607,910 rs2227543 C/T SNL +
4 74,608,162 Novel T/A SNL +
4 74,608,163 Novel T/G SNL +
4 74,608,408 Novel C/CA SNL +
11 62,186,542 rs3741240 G/A SL
11 62,190,293 rs191704193 G/A SL
5 180,017,251 Novel C/A SL
5 180,017,252 Novel C/G SL
5 180,017,597 Novel T/C SL
14 35,871,168 Novel C/CT SL
5 180,017,797 Novel G/GA SL
NA: not Available, CS: current smokers, SNL: smokers with no lung cancer, SL: smokers with lusecretoglobin using extensive molecular dynamics study in order to
ﬁnd the effect of frameshift and non-synonymousmutation in structural
level.Acknowledgment
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